Haloperidol
- Generic Name
- Haloperidol
- Brand Names
- Haldol
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23ClFNO2
- CAS Number
- 52-86-8
- Unique Ingredient Identifier
- J6292F8L3D
- Background
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularl...
- Indication
Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted ...
- Associated Conditions
- Aggression, Delirium, Gilles de la Tourette's Syndrome, Huntington's Disease (HD), Nausea and vomiting, Obsessive Compulsive Disorder (OCD), Psychosis, Schizophrenia, Severe Disruptive Behaviour Disorders, Severe Hyperactivity
- Associated Therapies
- -
A Comparison of Dexmedetomidine and Haloperidol in Patients With Intensive Care Unit (ICU)-Associated Agitation and Delirium
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Austin Health
- Target Recruit Count
- 20
- Registration Number
- NCT00505804
Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia
- Conditions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00485901
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
- Conditions
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 72
- Registration Number
- NCT00457366
- Locations
- 🇺🇸
Los Angeles County Hospital, Los Angeles, California, United States
Pilot Study of Haloperidol to Treat Critical Illness Delirium
- Conditions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 20
- Registration Number
- NCT00429676
- Locations
- 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States
Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2008-09-16
- Lead Sponsor
- University of Jena
- Target Recruit Count
- 19
- Registration Number
- NCT00419653
Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
- Conditions
- Interventions
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Duke University
- Target Recruit Count
- 72
- Registration Number
- NCT00340379
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇪🇬Alexandria University, Alexandria, Egypt
🇮🇳National Institute of Mental Health and Neuroscience, Bangalore, India
ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 40
- Registration Number
- NCT00300391
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 396
- Registration Number
- NCT00253110
Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Bronovo Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT00250237
- Locations
- 🇳🇱
Bronovo Hospital, The Hague, Zuid Holland, Netherlands
Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT00191555
- Locations
- 🇫🇷
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) , or speak with your personal physician, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.